GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Achillion Pharmaceuticals, Inc. (ACHN) [hlAlert]

Rating:
Buy ACHN
up 622.11 %

Achillion Pharmaceuticals, Inc. (ACHN) rated Buy with price target $2.50 by ThinkEquity

Posted on: Tuesday,  Jan 27, 2009  8:25 AM ET by ThinkEquity

ThinkEquity rated Buy Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) on 01/27/2009, when the stock price was $1.04. Since
then, Achillion Pharmaceuticals, Inc. has gained 622.12% as of 10/07/2015's recent price of $7.51.
If you would have followed this ThinkEquity's recommendation on ACHN, you would have gained 622.11% of your investment in 2444 days.

Achillion Pharmaceuticals, Inc. (Achillion) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. Within the anti-infective market, it focuses on the development of antivirals for the treatment of chronic hepatitis C and the development of antibacterials for the treatment of resistant bacterial infections. As of December 31, 2008, Achillion focused its efforts on advancing two late-stage preclinical candidates: ACH-1095, an NS4A antagonist for the treatment of chronic hepatitis C, being developed in collaboration with Gilead Sciences, Inc. (Gilead), and ACH-1625, a protease inhibitor also for the treatment of chronic hepatitis C. It has a pipeline of other product candidates, for which it is seeking appropriate collaborative partners. These product candidates include elvucitabine for the treatment of human immunodeficiency virus (HIV) infection and ACH-702 for the treatment of serious bacterial infections.

Research is at the core of everything we do at ThinkEquity, and we're passionate about it. Employing a disciplined and rigorous process, we scrutinize the spectrum of forces at play in the growth sectors we cover. Starting with a top down analysis, we look closely at the megatrends and industry drivers that create opportunities for innovative companies. We then allocate our resources based on a long-range research roadmap that leads to deep domain expertise and a close working knowledge of the technologies, products, services and people that populate the growth sector landscape. In short, the sum result of the ThinkEquity research process is to identify and affiliate ourselves with the fastest growing private and public companies within our domain verticals.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/27/2009 8:25 AM Buy
None
1.04 2.50
as of 12/31/2009
1 Week up  29.42 %
1 Month up  105.23 %
3 Months up  169.37 %
1 YTD up  314.42 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy